KEYNOTE-811: First-line Pembrolizumab + Trastuzumab and Chemotherapy in HER2+ Metastatic Gastric or Gastroesophageal Junction Cancer

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Interim analysis of the KEYNOTE-811 trial shows significantly higher response rate and more durable responses with pembrolizumab added to first-line trastuzumab and chemotherapy in gastric or gastroesophageal junction cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 412 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings